Tag: pCODR


Health Canada Approves Alecensaro to Treat Rare Lung Cancer

Health Canada has approved Alecensaro (alectinib) to treat patients with a rare form of lung cancer. The drug is approved as a  first-line monotherapy for patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).

Read More

Health Canada Approves Kisqali for Stage IV Breast Cancer

Health Canada has approved Novartis’ Kisqali (ribociclib) in combination with an aromatase inhibitor for the initial treatment for advanced or metastatic breast cancer in which postmenopausal women are hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative.

Read More